Cyclacel Pharmaceuticals (CYCC) 0.62 $CYCC
Cyclacel Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 6:13AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 17th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York, New York. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs on Tuesday, February 10, 2015 at 10:00 a.m. EST in the Conrad room.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Biotech Weekly: When To Dash For The Trash (And When Not To)
Daniel Ward - at Seeking Alpha - Mon Feb 02, 8:40AM CST
KBIO: 0.45 (+0.06), CYCC: 0.62 (-0.01), TRGT: 2.50 (-0.01), SPHS: 0.44 (-0.01), ABIO: 0.70 (+0.03), APPY: 0.45 (-0.01), OCLS: 0.80 (-0.01)
Cyclacel Pharmaceuticals to Present at the Biotech Showcase(TM) 2015 Conference
GlobeNewswire - Tue Jan 06, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) "Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the Biotech Showcase 2015 conference being held at Parc 55 Wyndham San Francisco - Union Square in San Francisco, California. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 3:30 p.m. PST on Monday, January 12, 2015.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Billionaires Got Burned by These Six Struggling Stocks in 2014
at The Street - Sat Jan 03, 8:20AM CST
Last year was better for some billionaires than it was others. Bill Ackman’s theme song? 'All I Do Is Win.' Carl Icahn’s? 'Maybe Next Year.' Six stocks that really hurt.
CYCC: 0.62 (-0.01), S: 5.23 (+0.08), ADNC: 4.59 (-0.02), CONN: 24.69 (-0.07), TMUS: 31.75 (+0.16), LINE: 12.94 (+0.40), VLTC: 0.77 (-0.04)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.44 (-0.01), ASPX: 65.76 (+2.76), MDVN: 104.71 (+0.67), CYCC: 0.62 (-0.01), OPK: 13.80 (-0.28), NLNK: 38.84 (+1.51), JUNO: 40.52 (+0.18), REGN: 402.40 (+0.66), MYGN: 34.03 (+0.40), PFE: 34.64 (-0.23), IMGN: 7.19 (unch), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), BLRX: 1.87 (-0.02), OREX: 5.55 (+0.10), DVA: 73.10 (-3.29), BLCM: 20.00 (-0.81), CBST: 101.94 (+0.14), GILD: 101.90 (+1.10), GERN: 3.03 (unch), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Cyclacel Pharmaceuticals Down 5.6%, Shares Slide into the Red (CYCC)
Comtex SmarTrend(R) - Fri Dec 19, 10:10AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing penny stocks, down 5.6% to $0.68 on 1.2x average daily volume. Cyclacel Pharmaceuticals has traded 299,000 shares thus far today, vs. average volume of 243,000 shares per day. The stock has underperformed the Dow (-5.6% to the Dow's 0.2%) and underperformed the S&P 500 (-5.6% to the S&P's 0.3%) during today's trading.
CYCC: 0.62 (-0.01)
Cyclacel Now An Exercise In Futility
Stephen Simpson, CFA - at Seeking Alpha - Thu Dec 18, 5:30AM CST
CYCC: 0.62 (-0.01)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 100.76 (+1.98), CLDX: 20.97 (+0.53), CYCC: 0.62 (-0.01), IMMU: 3.84 (unch), EBS: 28.76 (-0.12), INCY: 75.94 (+0.28), TGTX: 13.13 (-0.19), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), CELGZ: 3.17 (-0.04)
Cyclacel Falls on Poor Acute Myeloid Leukemia Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 4:00PM CST
In the SEAMLESS study on sapacitabine, the DSMB found that the planned futility boundary has been crossed.
ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), CYCC: 0.62 (-0.01), SCMP: 15.32 (+0.04)
Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 17, 9:26AM CST
It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline updates.
CYCC: 0.62 (-0.01), CBST: 101.94 (+0.14), SPHS: 0.44 (-0.01), CCXI: 7.85 (+0.04), ALXN: 182.29 (+6.02), EXEL: 2.48 (+0.20)
Downgrade Alert for Cyclacel Pharmaceuticals (CYCC)
Comtex SmarTrend(R) - Wed Dec 17, 6:51AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) was downgraded from Outperform to Market Perform at JMP Securities today. The stock closed yesterday at $0.68 on volume of 5.4 million shares, above average daily volume of 68,000. Over the past year, Cyclacel Pharmaceuticals has traded in a range of $0.66 to $4.84 and closed yesterday at $0.68, 3% above that low. In the last five trading sessions, the 50-day moving average (MA) has fallen 1.6% while the 200-day MA has slid 0.8%.
CYCC: 0.62 (-0.01)
Nasdaq stocks posting largest volume increases
AP - Tue Dec 16, 5:41PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
QCCO: 1.67 (+0.01), CYCC: 0.62 (-0.01), RVBD: 20.85 (-0.03), NECB: 6.96 (unch), ISIG: 3.19 (unch), HGSH: 3.05 (-0.13), LNBB: 17.74 (-0.01), AIRT: 19.45 (+0.39), KFFB: 8.02 (-0.13), SMBC: 18.95 (-0.05), IROQ: 16.70 (unch), MFI: 10.43 (+0.23)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 11:47AM CST
FRO: 2.96 (+0.07), TLM: 7.63 (-0.03), ECR: 7.29 (+0.12), BBX: 14.29 (-0.23), WG: 6.69 (+0.28), HGSH: 3.05 (-0.13), NVGN: 2.79 (+0.17), TPLM: 5.68 (+0.06), TLOG: 5.12 (+0.36), CYCC: 0.62 (-0.01), SFY: 2.91 (+0.26), BBG: 12.56 (+0.55), WRES: 1.27 (+0.01), GOL: 3.85 (+0.01), NAV: 28.52 (+0.58), WYY: 1.50 (+0.02), FNJN: 2.77 (-0.36), LINE: 12.94 (+0.40), SCX: 20.98 (+0.05), WLDN: 14.40 (+0.19)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 8:10AM CST
FRO: 2.96 (+0.07), TLM: 7.63 (-0.03), PHMD: 1.68 (+0.04), SLXP: 152.35 (+3.17), BBEP: 7.85 (+0.32), EXAS: 25.56 (-0.54), NVGN: 2.79 (+0.17), MBT: 10.36 (+0.62), LPI: 13.25 (+0.81), CYCC: 0.62 (-0.01), GOL: 3.85 (+0.01), AUY: 4.13 (+0.13), ORAN: 18.52 (+0.07), YNDX: 17.00 (+0.59)
Cyclacel's sapacitabine unlikely to achieve efficacy endpoint in Phase 3 AML trial
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 7:11AM CST
CYCC: 0.62 (-0.01)
Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis
GlobeNewswire - Tue Dec 16, 6:00AM CST
- DSMB determined that the planned futility boundary has been crossed; but saw no reason for patients to discontinue from study -
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel ups revenues 133% in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:32AM CST
CYCC: 0.62 (-0.01)
Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:24PM CST
CYCC: 0.62 (-0.01)
Cyclacel Pharmaceuticals misses by $0.06
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:09PM CST
CYCC: 0.62 (-0.01)
Cyclacel Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 11, 3:05PM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the third quarter ended September 30, 2014.
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 6:13AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 17th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York, New York. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs on Tuesday, February 10, 2015 at 10:00 a.m. EST in the Conrad room. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Biotech Weekly: When To Dash For The Trash (And When Not To)
Daniel Ward - at Seeking Alpha - Mon Feb 02, 8:40AM CST
KBIO: 0.45 (+0.06), CYCC: 0.62 (-0.01), TRGT: 2.50 (-0.01), SPHS: 0.44 (-0.01), ABIO: 0.70 (+0.03), APPY: 0.45 (-0.01), OCLS: 0.80 (-0.01)
Cyclacel Pharmaceuticals to Present at the Biotech Showcase(TM) 2015 Conference
GlobeNewswire - Tue Jan 06, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) "Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the Biotech Showcase 2015 conference being held at Parc 55 Wyndham San Francisco - Union Square in San Francisco, California. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 3:30 p.m. PST on Monday, January 12, 2015. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Billionaires Got Burned by These Six Struggling Stocks in 2014
at The Street - Sat Jan 03, 8:20AM CST
Last year was better for some billionaires than it was others. Bill Ackman’s theme song? 'All I Do Is Win.' Carl Icahn’s? 'Maybe Next Year.' Six stocks that really hurt.
CYCC: 0.62 (-0.01), S: 5.23 (+0.08), ADNC: 4.59 (-0.02), CONN: 24.69 (-0.07), TMUS: 31.75 (+0.16), LINE: 12.94 (+0.40), VLTC: 0.77 (-0.04)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.44 (-0.01), ASPX: 65.76 (+2.76), MDVN: 104.71 (+0.67), CYCC: 0.62 (-0.01), OPK: 13.80 (-0.28), NLNK: 38.84 (+1.51), JUNO: 40.52 (+0.18), REGN: 402.40 (+0.66), MYGN: 34.03 (+0.40), PFE: 34.64 (-0.23), IMGN: 7.19 (unch), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), BLRX: 1.87 (-0.02), OREX: 5.55 (+0.10), DVA: 73.10 (-3.29), BLCM: 20.00 (-0.81), CBST: 101.94 (+0.14), GILD: 101.90 (+1.10), GERN: 3.03 (unch), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Cyclacel Pharmaceuticals Down 5.6%, Shares Slide into the Red (CYCC)
Comtex SmarTrend(R) - Fri Dec 19, 10:10AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing penny stocks, down 5.6% to $0.68 on 1.2x average daily volume. Cyclacel Pharmaceuticals has traded 299,000 shares thus far today, vs. average volume of 243,000 shares per day. The stock has underperformed the Dow (-5.6% to the Dow's 0.2%) and underperformed the S&P 500 (-5.6% to the S&P's 0.3%) during today's trading.
CYCC: 0.62 (-0.01)
Cyclacel Now An Exercise In Futility
Stephen Simpson, CFA - at Seeking Alpha - Thu Dec 18, 5:30AM CST
CYCC: 0.62 (-0.01)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 100.76 (+1.98), CLDX: 20.97 (+0.53), CYCC: 0.62 (-0.01), IMMU: 3.84 (unch), EBS: 28.76 (-0.12), INCY: 75.94 (+0.28), TGTX: 13.13 (-0.19), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), CELGZ: 3.17 (-0.04)
Cyclacel Falls on Poor Acute Myeloid Leukemia Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 4:00PM CST
In the SEAMLESS study on sapacitabine, the DSMB found that the planned futility boundary has been crossed.
ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), CYCC: 0.62 (-0.01), SCMP: 15.32 (+0.04)
Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 17, 9:26AM CST
It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline updates.
CYCC: 0.62 (-0.01), CBST: 101.94 (+0.14), SPHS: 0.44 (-0.01), CCXI: 7.85 (+0.04), ALXN: 182.29 (+6.02), EXEL: 2.48 (+0.20)
Downgrade Alert for Cyclacel Pharmaceuticals (CYCC)
Comtex SmarTrend(R) - Wed Dec 17, 6:51AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) was downgraded from Outperform to Market Perform at JMP Securities today. The stock closed yesterday at $0.68 on volume of 5.4 million shares, above average daily volume of 68,000. Over the past year, Cyclacel Pharmaceuticals has traded in a range of $0.66 to $4.84 and closed yesterday at $0.68, 3% above that low. In the last five trading sessions, the 50-day moving average (MA) has fallen 1.6% while the 200-day MA has slid 0.8%.
CYCC: 0.62 (-0.01)
Nasdaq stocks posting largest volume increases
AP - Tue Dec 16, 5:41PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
QCCO: 1.67 (+0.01), CYCC: 0.62 (-0.01), RVBD: 20.85 (-0.03), NECB: 6.96 (unch), ISIG: 3.19 (unch), HGSH: 3.05 (-0.13), LNBB: 17.74 (-0.01), AIRT: 19.45 (+0.39), KFFB: 8.02 (-0.13), SMBC: 18.95 (-0.05), IROQ: 16.70 (unch), MFI: 10.43 (+0.23)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 11:47AM CST
FRO: 2.96 (+0.07), TLM: 7.63 (-0.03), ECR: 7.29 (+0.12), BBX: 14.29 (-0.23), WG: 6.69 (+0.28), HGSH: 3.05 (-0.13), NVGN: 2.79 (+0.17), TPLM: 5.68 (+0.06), TLOG: 5.12 (+0.36), CYCC: 0.62 (-0.01), SFY: 2.91 (+0.26), BBG: 12.56 (+0.55), WRES: 1.27 (+0.01), GOL: 3.85 (+0.01), NAV: 28.52 (+0.58), WYY: 1.50 (+0.02), FNJN: 2.77 (-0.36), LINE: 12.94 (+0.40), SCX: 20.98 (+0.05), WLDN: 14.40 (+0.19)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 8:10AM CST
FRO: 2.96 (+0.07), TLM: 7.63 (-0.03), PHMD: 1.68 (+0.04), SLXP: 152.35 (+3.17), BBEP: 7.85 (+0.32), EXAS: 25.56 (-0.54), NVGN: 2.79 (+0.17), MBT: 10.36 (+0.62), LPI: 13.25 (+0.81), CYCC: 0.62 (-0.01), GOL: 3.85 (+0.01), AUY: 4.13 (+0.13), ORAN: 18.52 (+0.07), YNDX: 17.00 (+0.59)
Cyclacel's sapacitabine unlikely to achieve efficacy endpoint in Phase 3 AML trial
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 7:11AM CST
CYCC: 0.62 (-0.01)
Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis
GlobeNewswire - Tue Dec 16, 6:00AM CST
- DSMB determined that the planned futility boundary has been crossed; but saw no reason for patients to discontinue from study -
CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
Cyclacel ups revenues 133% in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:32AM CST
CYCC: 0.62 (-0.01)
Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:24PM CST
CYCC: 0.62 (-0.01)
Cyclacel Pharmaceuticals misses by $0.06
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:09PM CST
CYCC: 0.62 (-0.01)
Cyclacel Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 11, 3:05PM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the third quarter ended September 30, 2014. CYCC: 0.62 (-0.01), CYCCP: 6.47 (-0.22)
